The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
ERS Data Support Web-Based Management to Increase Physical Activity in COPD Population
These data support web-based self-management for individuals with COPD with an objective, clinically relevant, short-term increase in physical activity levels compared to usual care.
Phase 2b Study Supports Icenticaftor for Patients with COPD, Chronic Bronchitis
“From this study it makes sense that the (icenticaftor) 300mg dose has a benefit-risk profile to further study the clinical benefits,” Dr. Frits Franssen, lead investigator, said at ERS Congress 2022.
Rising Temperatures Detrimental to Renal Function in Heart Failure Outpatients
Temperatures changes between summer and the rest of the year correlated with the magnitude of decrease in renal function during summer.
Fish Oil Supplement Intake Influences Long-Term Atrial Fibrillation Risk
Increased risk of AF by fish oil supplement was found to be prominent in low risk participants with healthy lifestyles.
Full-Dose Anticoagulation Lowers Thrombotic Event Risk in Patients with COVID-19
Full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications in critically-ill patients with COVID-19.
Atrial Fibrillation Screening Using Smartphones Significantly Increases Detection Rate
Digital screening more than doubled the detection rate of treatment-relevant AF in both phases of eBRAVE-AF trial.
Blood Pressure Targets Show No Benefit in Comatose Survivors of Cardiac Arrest
Targeting a mean arterial blood pressure of 77 mm Hg or 63 mm Hg was not associated with significantly different percentages of patients dying or having severe disability or coma.
SGLT2 Inhibitor Therapy Foundational in Wide Range of Heart Failure Management
SGLT2 inhibitors reduce the risk of hospitalization for heart failure, extend survival, and improve overall health status, irrespective of ejection fraction, in patients with heart failure.
Sanjai Rao, MD: Long-Acting Injectables for Schizophrenia
Treatment adherence remains a concern in psychiatry.
Polypill Strategy Lowers Adverse CV Event Risk in Secondary Prevention
The treatment strategy led to lower risk of major adverse cardiovascular events than usual care in older patients with recent myocardial infarction.
Suboptimal Sleep Linked to Greater Likelihood of Heart Disease
The risk of coronary heart disease and stroke decreased by 22% for every 1 point rise in the sleep score at baseline.
John J. Miller, MD: A New Era For Psychiatric Medications
The FDA approved esketamine in 2019 for major depressive disorder.
Anita Clayton, MD: Women's Issues in Psychiatry
Postpartum depression rates have increased since the COVID-19 pandemic.
Michael Thase, MD: Risk Factors for Chronically Depressed Patients
Alcohol, stress, drug use, and not seeking help are all risk factors for chronic depression.
John J. Miller, MD: Guidance on Cannabis Use in Psychiatry
CBD has shown promise in treating anxiety and psychosis.
Christopher Schneck, MD: Early Interventions for Bipolar Disorder
There remains a need for better treatments for bipolar disorder when it is identified early.
Joseph Goldberg, MD: Treating Mixed Feature Depression
Mixed feature depression can be difficult to diagnose because the symptoms can be similar to other psychiatric disorders.
M. Katherine Shear, MD: Addressing Grief After a Loss
There remains a need for more research into the connection between grief and depression following a death.
Larry Culpepper, MD: The Challenge of Treating BPD
Borderline personality disorder remains one of the most difficult to understand conditions in psychiatry.
Michael Thase, MD: New Medications for Treatment-Resistant Depression
Esketamine is seen as a major breakthrough in finding more treatments for depression.
M. Katherine Shear, MD: Bereavement and Depression
Dr. Shear talked about the similarities and differences between depression and grief and the importance of recognizing both.
Robert Kushner, MD: An Emphasis on Obesity as CV Risk Factor
Dr. Kushner discusses obesity as a risk factor for CVD and how preventive cardiologists can better target weight management to support patient health.
Arshad Khanani, MD: Durability of Faricimab for nAMD Based on Two-Year Data
Over 60% of patients in the second year of TENAYA and LUCERNE were on 16 week dosing in the faricimab group.
Yasha Modi, MD: Machine Learning Helps Predict Visual Outcomes, Treatment Patterns
Machine learning algorithms successfully predicted visual and anatomic outcomes and dosing frequency in patients with macular edema secondary to CRVO.
Theodore Leng, MD: Anti-VEGF Utilization Patterns in Patients with DME
Data show 77% of eyes with DME in the IRIS Registry received only one type of anti-VEGF agent over an average follow-up of 2.3 years.
Aleksandra Rachitskaya, MD: The Promise of PDS Despite Retinal Fluid Presence
The port delivery system provides good visual outcomes for patients with nAMD despite presence of fluid in post-hoc analysis of Archway trial.
David Lally, MD: Avacincaptad Pegol Shows Reduction of GA Lesion Growth
A post-hoc analysis of the GATHER1 trial suggests avacincaptad pegol reduced GA lesion growth across all distances from the foveal center point, when compared to sham.
Dilsher Dhoot, MD: Effect of Time to Aflibercept Injection on CRVO Outcomes
Longer time to intravitreal aflibercept injection (>3 months) showed less visual improvement versus shorter time (<1 month).
Dimitra Skondra, MD: Metformin May Serve as Novel Treatment for AMD
Data show metformin was associated with reduced odds of developing AMD, with low to moderate doses having the greatest potential benefit.
Rishi Singh, MD: Durability of EYP-1901 for Maintenance of nAMD
Dr. Singh discusses the promise of durability with the agent and the potential for reducing the amount of patient visits, while preserving visual outcomes.